Precigen (PGEN) Income towards Parent Company (2012 - 2026)
Precigen (PGEN) reported Income towards Parent Company of -$7.9 million for Q1 2026, up 85.36% year-over-year from -$4.3 million in Q1 2025, and up 66.26% quarter-over-quarter from -$23.5 million in Q4 2025.
Precigen (PGEN) Income towards Parent Company (2012 - 2026) Analysis & Trends
Precigen (PGEN) has 14 years of Income towards Parent Company data on file, last reported at -$7.9 million in Q1 2026.
- Income towards Parent Company for Q1 2026 came in at -$7.9 million, up 85.36% year-over-year; the trailing twelve-month figure through Mar 2026 was -$204.4 million (down 30.49% YoY), and the FY2025 annual result was -$250.6 million, changed N/A from the prior year.
- Income towards Parent Company advanced to -$7.9 million in Q1 2026 per PGEN's latest filing, from -$23.5 million in the prior quarter.
- Over five years, Income towards Parent Company peaked at $95.0 million in Q3 2022 and troughed at -$146.3 million in Q3 2025.
- A 4-year average of -$23.1 million and a median of -$23.6 million in 2024 frame the typical range for Income towards Parent Company.
- The sharpest annual moves came in 2022 and 2025: Income towards Parent Company surged 2858.29% in 2022, then plunged 510.33% in 2025.
- A 4-year view of Income towards Parent Company shows it stood at $95.0 million in 2022, then slumped by 120.76% to -$19.7 million in 2024, then slipped by 19.14% to -$23.5 million in 2025, then soared by 66.26% to -$7.9 million in 2026.
- Business Quant data shows PGEN's Income towards Parent Company at -$7.9 million in Q1 2026, -$23.5 million in Q4 2025, and -$146.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Precigen | 1.38 Bn | 1.38 Bn | 20.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.93 Mn |
| Dec 31, 2025 | -23.50 Mn |
| Sep 30, 2025 | -146.34 Mn |
| Jun 30, 2025 | -26.64 Mn |
| Mar 31, 2025 | -54.15 Mn |
| Dec 31, 2024 | -19.73 Mn |
| Sep 30, 2024 | -23.98 Mn |
| Jun 30, 2024 | -58.79 Mn |
| Mar 31, 2024 | -23.74 Mn |
| Sep 30, 2022 | 95.02 Mn |
| Jun 30, 2022 | 8.42 Mn |
| Mar 31, 2022 | 4.65 Mn |
| Dec 31, 2021 | 1.66 Mn |
| Sep 30, 2021 | -3.45 Mn |
| Jun 30, 2021 | 10.89 Mn |
| Mar 31, 2021 | 4.53 Mn |
| Dec 31, 2020 | -1.31 Mn |
| Sep 30, 2020 | -1.97 Mn |
| Jun 30, 2020 | -27.65 Mn |
| Mar 31, 2020 | -35.15 Mn |